# JOURNAVX

- **Website:** <https://journavx.com>
- **Primary alias:** `journavx.com`
- **Verified:** yes

## Description

JOURNAVX™ (suzetrigine) is a first-in-class, FDA-approved, oral non-opioid prescription pain medication developed by Vertex Pharmaceuticals, approved on January 30, 2025 — marking the first new class of acute pain treatment approved by the FDA in over 20 years. A highly selective NaV1.8 pain signal inhibitor, JOURNAVX works by blocking pain signals in the peripheral nervous system before they reach the brain — delivering effective relief for adults with moderate-to-severe acute pain caused by surgery, injury, or accident, with no evidence of addictive potential. The journavxpap.com portal specifically serves as the Patient Assistance Program gateway, helping eligible patients access JOURNAVX regardless of their ability to pay.

## Industries

- ⛑ Health
- ⛑ Biotechnology and Pharmaceuticals _(under Health)_

## Links

- [facebook](https://facebook.com/journavx)
- [instagram](https://instagram.com/journavx)

## Colors

| Name | Hex | Theme |
| --- | --- | --- |
| Cherry Pie | #2b034d | dark |
| Deep Blush | #e35fb4 | light |
| True V | #876cd5 | accent |

## Fonts

- Gilroy-Bold — asset _(custom)_

---

_Source: <https://brandfetch.com/journavx.com>_
_See [/llms.txt](/llms.txt) for a full list of agent-readable pages, and [/auth.md](/auth.md) for how agents authenticate._